Dosing simulations support AD-214 IV product profile
Released
Released
Announcement PDF
25 September 2023
ASX Announcement
AD-214 CLINICAL DOSE SIMULATIONS SUPPORT TARGET IV DOSE REGIMEN,
SUGGEST PATH TO ENHANCED SC REGIMEN FOR PARTNERS
Key points
• A model of AD-214 bioavailability and receptor occupancy has been developed
to estimate likely therapeutic effective doses in humans
• Supports potential efficacy of target intravenous doses of AD-214
• Suggests that subcutaneous administration could also be effective
• Combined results reduce Phase II risk and significantly enhance partnering
potential
• Results presentation at international Discovery on Target conference in
Boston, USA
MELBOURNE Australia, 25 September 2023: AdAlta Limited (ASX:1AD), the clinical stage
drug discovery company developing novel protein and cell therapeutic products from its
i-body platform, is pleased to report results of dose simulation studies which support the
potential efficacy of AD-214 in fibrotic disease at planned Phase II doses. The simulations
also highlight the possibility that AD-214 could be delivered subcutaneously at lower doses,
further enhancing the potential of the product.
Key findings
Intravenous (IV) delivery (direct infusion via canula into a vein during a hospital or clinic visit):
the model suggests that a clinically feasible dosing regimen of 10 mg/kg of AD-214
administered IV every two weeks bind its target receptor, CXCR4, and maintains levels of
receptor occupancy necessary to materially inhibit a model fibrosis process. This dosing
regimen is being used in the current Phase I extension clinical trial and would likely be
progressed in a Phase II clinical trial.
Subcutaneous (SC) delivery (administration under the skin via syringe, can be selfadministered by patients at home): the model was used to investigate the feasibility of
administering AD-214 subcutaneously, suggesting that target levels of receptor occupancy
could be achieved at doses of 1-3 mg/kg weekly, and less than 0.1 mg/kg daily. Not only is
SC administration more convenient for the patient, it also requires much less AD-214 (based
on the simulations), thus substantially reducing cost of goods. More work is required to verify
these results and develop a suitable formulation for subcutaneous use.
Dr Tim Oldham, CEO and Managing Director, commented:
“These simulations have resulted in two very important conclusions for AdAlta. Firstly, based
on our target product characteristics for commercial success, the target dosing regimen for
AD-214 has been 10 mg/kg IV every two weeks. The simulations further strengthen and
support the potential efficacy of this dosing regimen.
“Secondly, we have, for the first time, been able to explore the potential efficacy of
subcutaneously administered AD-214 under clinically convenient dosing regimens. While it
still makes sense to move forward to Phase II studies using intravenous AD-214, these
subcutaneous results add significant value to our partnering program by pointing the way to
a lower cost product in a more convenient format that patients could self-administer at home.
Our potential partners are genuinely excited by this method of delivery.”
The results of these dose simulation studies will be presented at the 20th Discovery on Target
conference in Boston, 25-28 September 2023 in a poster titled “Clinical dose estimation for
anti CXCR4 i-body-Fc fusion AD-214 for the treatment of fibrotic diseases”. Organised by the
Cambridge Healthtech Institute, Discovery on Target is the industry’s pre-eminent event on
novel drug targets and technologies. A copy of the poster is attached.
About the PK/PD model
Developing models of drug bioavailability (pharmacokinetics or PK) and target receptor
engagement or occupancy (pharmacodynamics or PD) is a valuable tool to assist in selecting
doses and dose regimens for clinical trials.
In collaboration with PK/PD modelling experts, Lyo-X, AdAlta has been able to develop a
model of AD-214 bioavailability that can accurately reproduce the PK and receptor occupancy
profiles observed in Phase I clinical studies.
Drug dosing regimens are selected to maintain a drug concentration and receptor occupancy
level, necessary to materially inhibit the progression of disease. Recent AdAlta studies1
showed that AD-214 receptor occupancy as low as 30% could materially inhibit a key fibrotic
process (immune and inflammatory cell migration). AD-214 maximally inhibited immune and
inflammatory cell migration at receptor occupancy of 60-85%.
Using these findings, the PK/PD model can be used to assess the likely efficacy of different
dosing regimens for AD-214.
Next steps
The results reported here reinforce the target IV product profile that AdAlta, in consultation
with its advisers, plans to continue through the current Phase I extension study and then into
Phase II (with partners).
The results also provide encouragement that an enhanced SC product profile is achievable.
Additional product development would be required to confirm these findings and develop a
subcutaneous form of AD-214 suitable for clinical use. Based on the positive response from
pharmaceutical companies with whom AdAlta has been able to share these findings, the
Company believes that a partner could potentially prepare a SC formulation of AD-214 ready
for introduction into Phase III clinical trials.
Authorised for lodgement by:
Tim Oldham
CEO and Managing Director
September 2023
Shareholders: please update your communication preferences
We encourage shareholders to update their share registry preferences
to receive all communications electronically. Doing so helps us
communicate with you in a time-efficient manner on important matters,
while minimising our mail costs and environmental impact.
Simply click here or scan the QR code and follow the instructions.
Not a shareholder, but want to keep across our progress? Click here to
subscribe to our updates using the Stay in Touch form.
1
ASX release 7 July 2023
Notes to Editors
PK/PD model results in more detail
The model was first asked to identify IV doses that could maintain greater than 30% receptor
occupancy for two weeks, the target interval between IV infusions required for reasonable
clinical adoption.
As described earlier, the results show that a dose of 10 mg/kg maintains greater than 30%
receptor occupancy (potential to materially inhibit fibrosis) throughout the two-week interval
between doses and greater than 60% receptor occupancy (potential to maximally inhibit
fibrosis) for at least 75% of that time (Figure 1A). This result supports the potential therapeutic
efficacy of this dosing regimen.
SC administration brings the possibility of patient self-administration at home which is
generally more convenient than IV infusions, which usually take place in clinics or hospitals.
The PK/PD model was therefore adapted to simulate SC administration and asked to identify
SC AD-214 dose regimens that could match or exceed the receptor occupancy profile
achieved with 10 mg/kg IV every two weeks. The simulations focused on weekly and daily
intervals between doses, the interval between SC injections required for reasonable clinical
adoption and high compliance.
The simulation results showed that 1-3 mg/kg weekly (Figure 1B) and 0.1 mg/kg or lower
daily (results not shown) could achieve or exceed the target receptor occupancy believed
necessary to inhibit fibrosis. These dosing regimens offer the added benefit of requiring less
total AD-214 over a year of therapy, substantially reducing the cost of goods. This is
particularly valuable in markets other than the USA where market prices for antifibrotic drugs
are lower.
A. Dosing every two weeks
10 mg/kg
B. Dosing every week
1 mg/kg
3 mg/kg
Days
Days
IV administration
SC administration
Maximal inhibition of fibrotic process
Meaningful inhibition of fibrotic process
Figure 1: Simulated CXCR4 receptor occupancy following IV (red) and SC (blue)
administration of AD-214 doses. Panel A simulates 10 mg/kg AD-214 administered every two
weeks. Panel B simulates 1 mg/kg (left) and 3 mg/kg (right) AD-214 administered every week.
Shading represents receptor occupancy (RO) required for maximal (green) and meaningful
(more than 50%, yellow) inhibition of a model fibrotic process in ex vivo experiments.
About AdAlta
AdAlta Limited is a clinical stage drug development company headquartered in Melbourne,
Australia. The Company is using its proprietary i-body technology platform to solve
challenging drug targeting problems and generate a promising new class of single domain
antibody enabled protein and cell therapeutics with the potential to treat some of today’s most
challenging medical conditions.
The i-body technology mimics the shape and stability of a unique and versatile antigen
binding domain that was discovered initially in sharks and then developed as a human
protein. The result is a range of unique proteins capable of interacting with high selectivity,
specificity and affinity with previously difficult to access targets such as G-protein coupled
receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully
human single domain antibody scaffold and the first based on the shark motif to reach clinical
trials.
AdAlta is extending Phase I clinical studies for its lead i-body candidate, AD-214, that is being
developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic
diseases for which current therapies are sub-optimal and there is a high unmet medical need.
Preparation for Phase II clinical studies is also underway. AdAlta has a second target in
discovery research, also in the field of fibrosis and inflammation.
The Company is also entering collaborative partnerships to advance the development of its
ibody platform. It has a collaboration with Carina Biotech to co-develop precision engineered,
i-body enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It
has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents
(iPET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a
program now in preclinical development.
AdAlta’s strategy is to maximise the products developed using its next generation i-body
platform by internally discovering and developing selected i-body enabled product candidates
against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other
biopharmaceutical companies to develop product candidates against other classes of
receptor, in other indications, and in other product formats.
Further information can be found at: https://adalta.com.au
For more information, please contact:
Investors
Media
Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au
IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au
Clinical dose estimation for anti CXCR4 i-body-Fc fusion AD-214 for
the treatment of fibrotic diseases
Jason P. Lynch1; Louise Organ1; Tim Oldham1; Lionel Renaud2; Bastien Casini2; Mattias Machacek2; Michael Foley1,3
AdAlta Ltd, Bundoora, Bundoora, Melbourne Australia 3083; 3083; 2Lyo-X-AG, Henric-Petri Strasse 6, Basel, Switzerland, 4051; 3La Trobe University, Bundoora, Melbourne, Australia
1
A
Background
•
i-bodies are small, stable, human scaffolds inspired by shark single
domain antibodies. i-body-Fc-fusion AD-214 has specificity and
picomolar affinity for CXCR4, a GPCR upregulated in fibrosis.
•
AD-214 has been specifically designed for fibrotic disease, has
demonstrated anti-fibrotic activity in several preclinical models and
was found to be well tolerated in a Phase I clinical trial.
•
AD-214 maintained >60% receptor occupancy (RO, blocking) for up
to three weeks after IV infusion however this had not been
correlated with efficacy, making dose estimation challenging
B
i-body
CXCR4
Fig. 1 (A) Ribbon diagram showing i-body bound to CXCR4. (B) Graphical Abstract.
Aims
• To determine levels of RO required to achieve efficacy
• To determine clinically convenient IV and SC dosing regimens (two weeks between IV doses, daily or weekly SC doses) that maintain the RO levels required to achieve efficacy
Maximal inhibition of T cell migration can be achieved with just 60-85% CXCR4 receptor occupancy and low serum concentrations of AD-214
21H5-Fc
100
50
0
20 40 60 80 100
Donor 2
150
AD-214
100
50
0
20
CXCR4 RO (%)
40
60
80 100
% inhibition of migration
• 1 nM of AD-214 (serum concentration detectable in
clinical trial participants 72h after IV, 10 mg/kg AD214) achieves high (57-85%) CXCR4 occupancy and
maximally inhibits SDF-1⍺ induced T cell migration.
AD-214
% inhibition of migration
• The correlation of inhibition of migration with CXCR4
receptor occupancy (RO) enables a target RO for
therapeutic efficacy to be estimated
Donor 1
150
% inhibition of migration
• Ex vivo, SDF-1⍺ induced migration of primary human
T cells models migration of inflammatory cells, a key
fibrotic process on which AD-214 acts.
CXCR4 RO (%)
150
Donor 3
Inhibition of CD3+ T cell
migration
%RO
Maximal
inhibition
[AD-214]
%RO
IC50
[AD-214]
AD-214
100
50
20 40 60 80 100
10-40% RO for
meaningful inhibition1
80
60
40
20
0
•
•
•
40
20
LLOQ
40
20
0
0
0 20 40 60 80 100120
% Inhibition of migration
Target 50+% inhibition for of cell
migration for meaningful
efficacy
60
0
0 20 40 60 80 100120
% Inhibition of migration
Target 80+% inhibition of cell
migration for maximum efficacy
1
2
3
4
Time since end of infusion (weeks)
Can be readily achieved for 2-3
weeks following a single IV
infusion2
3
Q
Q2
𝑘 !"# = 𝑅0 ⋅ 𝑘 $%&
AD-214
Non-Linear
Elimination
(𝐾) , 𝑉) )
+
Linear
Elimination
(𝐶𝑙)
CXCR4
receptors
𝑘 $%&
kon
koff = KD·kon
AD-214:
CXCR4
complex
V1
𝑘 '#(
Receptor Occupancy %
Predicted CXCR4 RO at trough after q1d, q1w, q2w
and q3w IV and SC doses
V3
AD-214
q2w ≥5 mg/kg IV or SC predicted to achieve target plasma
[AD-214] and RO
•
20
60
80
Fig. 3 (A). RO and migration data from Fig 2. (B) RO from a Phase I trial of healthy volunteers injected IV with various doses of AD-214 as shown.
AD-214
Days
40
80
20 40 60 80 100
100
90
80
70
60
50
40
30
20
10
0
Model A
+PK
+RO
Model B
+PK
+RO
+total receptor
Q1W
Q1W
Q2W
Q2W
Q3W
Q3W
Q1D
Q1D
IV
SC
0.001 0.003 0.01 0.03 0.1
1
3
5
10
Dosing Regimen
Dosing Route
20
AD-214 (mg/kg)
Fig 4. A 3-compartmental model with parallel linear and non-linear elimination (Michaelis-Menten approximation) as well as
explicit receptor binding + complex internalization was able to fit the PK and CXCR4 RO observations more accurately than any
simpler model
Conclusions and future directions
60
5 mg/kg
10 mg/kg
20 mg/kg
100
% Inhibition of migration
1
V2
injection
80
Phase I
AD-214
100
0
0
B
Donor 3
AD-214
CXCR4 RO (%)
2
100
CXCR4 RO (%)
CXCR4 RO (%)
60-80% RO for maximal
inhibition1
PK/PD model for AD-214 dose estimation
Donor 2
Donor 1
AD-214
21H5-Fc
100
• Phase I clinical trials show that these efficacious receptor
occupancy levels can be maintained for at least two weeks
after an IV infusion in humans, a clinically viable dosing
regimen
Fig 6. Predicted AD-214 serum
concentration and CXCR4 RO after q2w
IV and SC doses in a typical 70-kg
individual. Horizontal dashed lines are
the target RO of 30%, 60-85%. Model B
(run 083) fitted to PK + RO + total
CXCR4 data.
85%
1 nM
37%
0.1 nM
CXCR4 RO (%)
CXCR4 RO (%)
A
• Maintaining efficacious receptor occupancy levels is the
objective of dose selection
• Preclinical PK results and reasonable
assumptions allowed this to be
extrapolated to SC AD-214 administration.
Donor 3
57%
0.8 nM
11%
0.07 nM
Table 1 Concentrations of AD-214 and CXCR4 RO required
to achieve the indicated levels of migration inhibition.
0
Clinically feasible, two weekly or longer IV dosing regimens can support sufficient receptor occupancy (RO) to inhibit fibrotic processes
• A model of IV AD-214 administration was
developed and validated using SPR derived
binding data and Phase I human PK, RO
1-hour
data (Model A) and additionally CXCR4
IV infusion
expression data (Model B).
or SC
Donor 2
57%
0.7 nM
22%
0.15 nM
Fig. 2 (A) Primary human CD3+ T cells treated with a concentration gradient of AD-214 for 15 mins at 37 oC were loaded onto a transwell plate with AD-214
present or washed and analysed for CXCR4 occupancy and migration. AD-214 was detected using AF647-conjugated anti-H+L secondary antibody and free CXCR4
using a competing anti-CXCR4 (clone 12G5)-BrilliantViolet421 antibody. %RO = 100 x (normalizedOCCUPIED / normalizedOCCUPIED + normalizedFREE). For
migration assays, SDF-1⍺ (10 nM) induced migration across the transwell was quantified 2.5 h later and results were expressed as % inhibition by AD-214 relative
to minimum (zero SDF-1) and maximum (+SDF-1) in each donor. Error bars denote SEM; technical replicates: n = 3 for donors 1 and 3, n = 2 for donor 2.
• Meaningful (>50%) inhibition can be achieved at 0.10.2 nM AD-214
• Ex vivo RO and T cell migration results
suggest target RO levels for anti-fibrotic
efficacy of 30% (minimum 50% inhibition of
fibrosis at trough) to 60%-85% (range of RO
required to maximally inhibit fibrosis in all
donors at trough)
Donor 1
Fig 5. Predicted steady-state CXCR4 RO at trough in a typical 70-kg individual for different repeated SC
and IV dose regimens. Horizontal dashed lines are the target RO of 30%, 60% and 85%. Model A, fitted
to PK + RO data. Model B, fitted to PK + RO + total CXCR4 data.
q1w ≥1 mg/kg IV or SC predicted to achieve target plasma
[AD-214] and RO
Fig 7. Predicted AD-214 serum
concentration and CXCR4 RO after q1w
IV and SC doses in a typical 70-kg
individual. Horizontal dashed lines are
the target RO of 30%, 60-85%. Model B
(run 083) fitted to PK + RO + total
CXCR4 data.
Days
q1d ≥0.01 mg/kg SC predicted to achieve
target plasma [AD-214] and RO
Fig 8. Predicted CXCR4 RO after q1day SC doses of
0.001 to 0.1 mg/kg in a typical 70-kg individual.
Horizontal dashed lines are the target RO of 30%,
60-85%. Model B (run 083) fitted to PK + RO + total
CXCR4 data.
Ex vivo studies correlating receptor occupancy and inhibition of a model fibrotic process (cell migration) at serum concentrations achieved during Phase I clinical studies are reported, alongside PK
and receptor occupancy simulations.
Phase I clinical results and simulation experiments support the hypothesis that clinically feasible q2w intravenous dosing regimen is likely to be efficacious in fibrotic disease.
Further, an even more convenient q1d or q1w SC administration regimen may also be efficacious.
AD-214 multidose Phase I extension clinical study underway evaluating safety PK and PD of multiple 10 mg/kg doses (final results Q1 2024):
ü
Strengthens safety profile: establishes safety and tolerability at likely maximum dose to be used in Phase II studies
ü
Further validates PK/PD model to better inform Phase II dose regimen selection: further explores PK, PD and safety trends observed in Phase I
Share your feedback
Discover